Gapping up
In reaction to strong earnings/guidance/SSS:
- CHS +17% (raises Q4 outlook; CFO has resigned), AZZ +11.3%, ADMA +8.9%, FOLD +5.7%, HELE +5%, AXNX +4%, BKE +3.2%, JEF +2.5%, LNN +2.4%, PCRX +2%, COST +0.9% (reports comps of +9%), T +0.6%
Select financial China related names showing strength:
- BIDU +2.2%, BABA +1.7%, WB +1.4%, JD +1.2%, ASHR +0.5%
Other news:
- AGTC +65.6% (reported positive interim six-month data from its ongoing Phase 1/2 clinical program in X-linked retinitis pigmentosa)
- DBVT +21.4% (reports positive top-line results for Phase 3 PEPITES trial)
- NBRV +8.1% (FDA acknowledges receipt of NDA resubmission for CONTEPO)
- MIRM +4.8% (prices offering of 2.4 mln shares of common stock at $20.00 per share)
- APLS +2.5% (prices offering of 9.5 mln shares of its common stock at $37.00/share)
- RGNX +1.1% (corporate update)
- MRK +0.5% (gets FDA approval of KEYTRUDA for certain patients)
- MDB +0.5% (files for $750 mln in convertible notes offering), .
Analyst comments:
- AMD +2.3% (upgraded to Buy from Neutral at Mizuho)
- MDGL +2% (upgraded to Buy from Neutral at UBS)
- BDSI +1.8% (initiated with an Overweight at Piper Sandler)
- APTO +1.5% (initiated with an Overweight at Piper Sandler)
- GS +1.4% (upgraded to Buy from Neutral at BofA/Merrill)
- CTSH +1.3% (upgraded to Overweight from Equal Weight at Wells Fargo)
- NATI +1.3% (upgraded to Outperform from Neutral at Robert W. Baird)
- CDK +1.2% (upgraded to Overweight from Equal Weight at Wells Fargo)
- K +1.1% (upgraded to Outperform from Market Perform at BMO Capital Markets)
- C +1.1% (initiated with a Buy at DA Davidson)
- KO +0.9% (upgraded to Outperform from Neutral at Credit Suisse)